Heart drug dobutamine put to the test in rare amyloid heart disease
NCT ID NCT06318260
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is studying how the drug dobutamine affects the heart in 15 people with a rare condition called wild-type transthyretin amyloid cardiomyopathy (ATTRwt). Participants will receive increasing doses of dobutamine while doctors measure heart function using ultrasound and a catheter. The goal is to see how the drug changes blood flow and heart pressures, and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dobutamine (Dobutrex)
- What this could lead to
- If successful, this could help doctors understand whether dobutamine can safely improve heart function in people with this type of heart disease.
- What could go wrong
- This is a very small, early-phase study with only 15 participants. It is designed to measure short-term effects, not to prove long-term benefit or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTR AMYLOIDOSIS WILD TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Cardiology, Aarhus University Hospital
RECRUITINGAarhus, 8200, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.